Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts
Author:
Moshe Talpaz,Ronald Paquette,Lawrence Afrin,Solomon Hamburg,Katarzyna Jamieson,Howard Terebelo,Gregory Ortega,Roger M. Lyons,Ramon V. Tiu,Elliott F. Winton,Kavita Natrajan,Olatoyosi Odenike,Wei Peng,Victor A. Sandor,Peter O'Neill et al.
Copyright © 2012 American Society of Hematology